Literature DB >> 15187504

Endocrinologic response to vasopressin infusion in advanced vasodilatory shock.

Martin W Dünser1, Walter R Hasibeder, Volker Wenzel, Siegfried Schwarz, Hanno Ulmer, Hans Knotzer, Werner Pajk, Barbara E Friesenecker, Andreas J Mayr.   

Abstract

OBJECTIVES: To evaluate the endocrinologic response to a combined arginine vasopressin and norepinephrine (AVP/NE) infusion in advanced vasodilatory shock, and to examine the relationship between baseline plasma AVP concentrations and the hemodynamic response to AVP.
DESIGN: Preliminary, prospective, randomized, controlled clinical study.
SETTING: Twenty-three-bed general and surgical intensive care unit. PATIENTS: Thirty-eight patients with advanced vasodilatory shock. Hemodynamic and laboratory data of 34 patients have already been presented in a recently published prospective, randomized, controlled study.
INTERVENTIONS: Continuous AVP (4 units/hr) and NE infusion in study patients; NE infusion only in control patients.
MEASUREMENTS AND MAIN RESULTS: At baseline, 24 hrs, and 48 hrs after randomization, plasma concentrations of AVP, adrenocorticotropic hormone, cortisol, renin, angiotensin II, aldosterone, prolactin, endothelin I, and atrial natriuretic factor were determined. Hemodynamic variables were recorded at baseline and 1, 12, and 24 hrs after randomization. Linear mixed effects models were used to test for differences between groups. The relationship between AVP plasma concentrations and hemodynamic response to AVP was analyzed using linear regression analyses. AVP/NE patients exhibited significantly higher AVP (p <.001) and prolactin (p <.001) plasma concentrations during the study period; there were no significant differences in plasma concentrations of other hormones. No significant correlation was detected between plasma AVP concentrations and the increase in mean arterial pressure after 1 hr (Pearson's correlation coefficient =.134, p =.584) and after 24 hrs (Pearson's correlation coefficient = -.198, p =.417). There were further no correlations between AVP plasma concentrations and the 24-hr response to AVP therapy in heart rate (Pearson's correlation coefficient = -.065, p =.791), stroke volume index (Pearson's correlation coefficient = -.106, p =.687), and NE requirements (Pearson's correlation coefficient =.04, p =.869).
CONCLUSIONS: The preliminary results of this study indicate that a combined AVP and NE infusion increases prolactin plasma concentrations in advanced vasodilatory shock. Hemodynamic effects of AVP infusion are independent of baseline plasma AVP concentrations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187504     DOI: 10.1097/01.ccm.0000127264.54807.b7

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

1.  Comment on "Role of vasopressin in the management of septic shock" by Mutlu and Factor.

Authors:  Martin W Dünser; Andreas J Mayr; Volker Wenzel; Walter R Hasibeder
Journal:  Intensive Care Med       Date:  2004-07-23       Impact factor: 17.440

2.  Proven infection-related sepsis induces a differential stress response early after ICU admission.

Authors:  Olivier Lesur; Jean-Francois Roussy; Frederic Chagnon; Nicole Gallo-Payet; Robert Dumaine; Philippe Sarret; Ahmed Chraibi; Lucie Chouinard; Bruno Hogue
Journal:  Crit Care       Date:  2010-07-09       Impact factor: 9.097

Review 3.  Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis.

Authors:  Angelo Polito; Emilio Parisini; Zaccaria Ricci; Sergio Picardo; Djillali Annane
Journal:  Intensive Care Med       Date:  2011-11-30       Impact factor: 17.440

4.  The cellular mechanisms underlying the inhibitory effects of isoflurane and sevoflurane on arginine vasopressin-induced vasoconstriction.

Authors:  Manabu Shimogai; Koji Ogawa; Yasuyuki Tokinaga; Akinori Yamazaki; Yoshio Hatano
Journal:  J Anesth       Date:  2010-10-17       Impact factor: 2.078

5.  Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials.

Authors:  Myura Nagendran; James A Russell; Keith R Walley; Stephen J Brett; Gavin D Perkins; Ludhmila Hajjar; Alexina J Mason; Deborah Ashby; Anthony C Gordon
Journal:  Intensive Care Med       Date:  2019-05-06       Impact factor: 17.440

6.  Vasopressin in the pediatric cardiac intensive care unit: Myth or reality.

Authors:  Vishal K Singh; Rajesh Sharma; Amit Agrawal; Amit Varma
Journal:  Ann Pediatr Cardiol       Date:  2009-01

Review 7.  Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.

Authors:  Matthias Lange; Christian Ertmer; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

8.  Vasopressin: Its current role in anesthetic practice.

Authors:  Jayanta K Mitra; Jayeeta Roy; Saikat Sengupta
Journal:  Indian J Crit Care Med       Date:  2011-04

9.  Dear vasopressin, where is your place in septic shock?

Authors:  Martin W Duenser; Walter R Hasibeder
Journal:  Crit Care       Date:  2004-11-15       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.